NeuroPace Completes $74.8M Public Offering, Plans Share Repurchase

NeuroPace, Inc. has successfully completed an underwritten public offering of 7,475,000 shares of common stock, generating approximately $74.8 million. The company plans to use around $49.5 million of the proceeds to repurchase 5.3 million shares from its major stockholder, KCK Ltd., at a price of $9.40 per share. This strategic repurchase aims to strengthen NeuroPace's balance sheet and support its long-term operations focused on treating drug-resistant epilepsy. Following this, NeuroPace will report its financial results for the fourth quarter and full year of 2024 on March 4, 2025. The company expresses confidence in its ability to achieve cash flow breakeven with the recent financing and ongoing investor support. NeuroPace continues to emphasize its commitment to advancing treatment options for epilepsy patients through its innovative RNS System.